GlassScriptPhysician profile
Emily D Briggs
NPI 1760514871
$3,527.68
in general payments reported to CMS, 2019-2025
22 companies · $906 in 2025
The $906 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $261 · 2021: $31.42 · 2022: $440 · 2023: $818 · 2024: $715 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,438.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $568.65 | 2023-2025 | Tavneos, Otezla, Repatha |
| Lilly USA, LLC | $412.04 | 2022-2025 | Mounjaro, Jardiance |
| Abbott Laboratories | $397.20 | 2019-2023 | Octrode |
| Medtronic, INC. | $332.46 | 2022-2025 | Kyphon Express II Kyphopak Tray, Inceptiv |
| Teva Pharmaceuticals USA, INC. | $260.74 | 2020 | |
| Abbvie INC. | $231.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $198.87 | 2022-2025 | Airsupra |
| Si-Bone, INC. | $171.60 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $131.40 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.42 | 2024 | |
| Cardiovascular Systems INC. | $103.62 | 2019 | |
| Pfizer INC. | $78.21 | 2025 | |
| Corium, LLC | $70.70 | 2022 | |
| Procept Biorobotics Corporation | $69.04 | 2025 | |
| Merck Sharp & Dohme LLC | $68.66 | 2024 | Capvaxive |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $67.74 | 2023 | Rexulti |
| Inspire Medical Systems, INC. | $61.71 | 2024 | Inspire |
| Organon LLC | $59.85 | 2022-2025 | Nexplanon |
| Novartis Pharmaceuticals Corporation | $55.58 | 2025 | |
| Alfasigma USA, INC. | $31.42 | 2021 | |
| Dexcom, INC. | $24.53 | 2024 | Dexcom G6 Transmitter |
| Optinose US, INC. | $20.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.